Synaptogenix Future Growth
Future criteria checks 0/6
Synaptogenix's earnings are forecast to decline at 27.3% per annum. EPS is expected to grow by 22.4% per annum.
Key information
-27.3%
Earnings growth rate
22.4%
EPS growth rate
| Biotechs earnings growth | 24.4% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 11 Jul 2024 |
Recent future growth updates
No updates
Recent updates
We Think Synaptogenix (NASDAQ:SNPX) Can Afford To Drive Business Growth
Sep 20
Companies Like Synaptogenix (NASDAQ:SNPX) Are In A Position To Invest In Growth
May 10Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment
Nov 17Synaptogenix (NASDAQ:SNPX) Is In A Good Position To Deliver On Growth Plans
Oct 05Synaptogenix: The Next Big Thing In Alzheimer's
Jun 16Synaptogenix provides update on phase 2b Alzheimer's disease trial
Jun 09We're Keeping An Eye On Synaptogenix's (NASDAQ:SNPX) Cash Burn Rate
Jun 09Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -21 | N/A | N/A | 1 |
| 12/31/2025 | N/A | -13 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -8 | N/A | N/A | 1 |
| 3/31/2024 | N/A | -12 | -5 | -5 | N/A |
| 12/31/2023 | N/A | -14 | -5 | -5 | N/A |
| 9/30/2023 | N/A | -8 | -7 | -7 | N/A |
| 6/30/2023 | N/A | -11 | -8 | -8 | N/A |
| 3/31/2023 | N/A | -4 | -9 | -9 | N/A |
| 12/31/2022 | N/A | -6 | -11 | -11 | N/A |
| 9/30/2022 | N/A | -14 | -10 | -10 | N/A |
| 6/30/2022 | N/A | -14 | -9 | -9 | N/A |
| 3/31/2022 | N/A | -13 | -9 | -9 | N/A |
| 12/31/2021 | N/A | -13 | -9 | -9 | N/A |
| 9/30/2021 | N/A | -14 | -8 | -8 | N/A |
| 6/30/2021 | N/A | -15 | -10 | -10 | N/A |
| 3/31/2021 | N/A | -16 | -10 | -10 | N/A |
| 12/31/2020 | N/A | -15 | -8 | -8 | N/A |
| 9/30/2020 | N/A | -12 | -8 | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SNPX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SNPX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SNPX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if SNPX's revenue is forecast to grow faster than the US market.
High Growth Revenue: SNPX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SNPX's Return on Equity is forecast to be high in 3 years time